SpringWorks to present long-term efficacy and safety data from phase 3 DeFi trial of Ogsiveo in adults with desmoid tumours at CTOS 2024 meeting: Stamford, Connecticut Saturday, N ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback